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Adoptive T-cell therapy to treat liver cancer: Is the liver 
microenvironment key?
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Hepatocellular carcinoma (HCC) reflects the 5th most 
common cause for cancer related deaths worldwide with 
approximately 800.000 deceases per year and is the third most 
frequent cause for death worldwide [1]. In African or Asian 
countries HCC has become the most common cause for cancer-
related death, mainly as a consequence of viral infections with 
Hepatitis B and C-viruses (HBV; HCV). Notably, in Europe and 
the USA HCC is on the rise, reflecting the fastest increasing 
cancer type in recent years in the USA. Prospectively this trend 
will worsen in the USA and Europe since e.g. HCV had already 
superseded HIV as a cause of death. Moreover, in industrialized 
countries not only HBV- or HCV-infections surmount this 
development but more and more high fat diet induced non-
alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver 
disease (NAFLD) lead to liver cancer [1]. Given the effort that 
has been invested in the past year to understand and treat HCC 
- either induced by viruses, high fat diet or chronic alcohol 
consumption - clinical success has been relatively small.  Up 
to now the most effective intervention to prolong life-span 
of HCC patients has been liver transplantation for those with 
a single, small nodule – which is the exception. Chemo- and 
radiotherapy do not lead to an amelioration of the patient´s 
status but rather to tumor cell resistance in patients with HCC. 
Moreover, the aberrant liver function of HCC patients rather 
reduces the efficacy of the chemotherapy than promoting it. 
Various novel drugs have been investigated, and the pan-
tyrosine kinase inhibitor Sorafenib [1] has become the standard 
of care for HCC therapy. Except transplantation, these regimens, 
however, are rather palliative than curative [1]. Thus, apart from 
the demand to broaden HCC surveillance programs to reduce 
overall disease specific mortality for people at risk, an efficient 
therapy to treat HCC is urgently needed.  In contrast to the 
antigenic heterogeneity of high fat diet or alcohol induced HCC, 
that express tumor-associated (self) antigens or individually 
mutated antigens, tumor cells of virus-induced HCC equally 
express - and may be addicted to - viral proteins, that are 
recognized by the immune system. Nevertheless, virus-induced 
HCC often escapes immune-surveillance. In a related virus-
induced HCC mouse model we have shown that tumor-specific 
T cells are functionally activated by the virus infection but 
that the developing HCC escapes destruction since T cells can 
only poorly infiltrate HCC and the few remaining, infiltrating 
T cells are rendered dysfunctional in the liver [2]. Therefore, 
immunotherapy for treating virus-induced HCC, in particular 
adoptively transferred T-cells targeted against viral oncogenes 
acting as shared tumor-specific antigens, could represent a very 
promising and successful approach.
For adoptive T cell therapy (ATT) two strategies to graft 
new specificities onto patients T cells are currently pursued 
and have already shown feasibility in preclinical trials and 
the clinic: (First) Genetic engineering of T cells with chimeric 
antigen receptors [3,4] or (Second) with cloned T cell receptors 
(TCRs; [5]) which recognize tissue/tumor-specific or tumor-
associated antigens. Whereas the first is useful to target surface 
antigens independent of the HLA molecule, the second allows 
also recognition of antigen cross-presented by the tumor stroma. 
This has recently been shown to be of utmost importance for 
preventing tumor recurrence, especially if the targeted antigenic 
peptides do not have enough affinity for the restricting HLA 
molecule [6]. Apart from the fact that both types of redirected T 
cells target foreign viral antigens that are not expressed on non-
infected normal tissue, it is advantageous for TCR-redirected 
T cells that most HBV and HCV viral epitopes, e.g. in the 
context of the HLA-A2 allele, have a predicted IC
50
 value of 
high affinity (below 100 nM). Recurrence after appropriate 
ATT is thus unlikely when tumor growth is dependent on the 
expression of the respective virus-derived proteins. To enhance 
the efficacy of ATT and to circumvent negative impact of the 
tumor microenvironment onto T cells, the transfer of redirected 
T cells can be accompanied with antibodies e.g. blocking 
immune regulatory PD-1 or Lag3 pathways. Additionally, 
the local expansion of adoptively transferred T-cells has to be 
increased to achieve higher T cell numbers. We have recently 
investigated this in detail and have found that changing 
the microenvironment in the liver by activation of toll-like 
receptors induced the transient existence of intrahepatic 
myeloid aggregates (iMATEs) which support T cell expansion 
e.g. enabling control of chronic hepatic viral infection after 
vaccination with DNA [7]. Thus, these novel applications that 
allow expansion of T-cells at the site of action could become 
more efficient to fight liver cancer and preserve the efficacy of 
adoptively transferred T-cells.
Importantly, it has recently been shown that inflammation, 
as often accompanied with HCC in patients with chronic HBV 
or HCV infection, dynamically fine-tunes antigen sensitivity of 
CD8+ T cells that subsequently gain enhanced effector potential 
to eliminate virus antigen positive cells [8]. However, how 
chronic inflammation and fibrosis or even acute modulation of 
the hepatic microenvironment will finally influence the efficacy 
of adoptively transferred CD8+ T cells remains largely unknown 
and thus has to be investigated thoroughly in future - first in 
relevant primary mouse models and then translated into the 
clinic. Accordingly, there are several pivotal questions open in 
the field of ATT and its possible use for the treatment of liver 
cancer:
• How to enable efficient anti-hepatoma activity of 
adoptively transferred T-cells at or within the tumor 
site?
• How to assure tumor antigen specificity of 
adoptively transferred T cells in HCC?
• How to control the effect of the liver tumor 
microenvironment (e.g. inflammation; fibrosis) on 
T cell expansion, T cell mediated tumor cell killing 
and survival. 
In conclusion, ATT is a highly auspicious strategy to treat 
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HCC. Still, the most efficient modality for ATT for the various 
HCC subtypes has to be determined, before this approach might 
become successful in the clinic.
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